Protocols
15 protocol(s) meet the specified criteria
Disease Site: Prostate
Protocol No.TitleStatus
A031201-CIRBPHASE III TRIAL OF ENZALUTAMIDE (NSC # 766085) VERSUS ENZALUTAMIDE, ABIRATERONE AND PREDNISONE FOR CASTRATION RESISTANT METASTATIC PROSTATE CANCEROpen (affiliates only)
AMC-095A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid TumorsOpen
C14-146A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or AbirateroneOpen
D6410C00001A Phase I, First-Time-in Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with Solid Tumor CancerOpen
LCCC1231LCCC 1231: Observational Longitudinal Study of Pain in Men with Metastatic Castrate-Resistant Prostate CancerOpen (affiliates only)
LCCC1512Evaluation of the accuracy of new-generation pedometers in older adult patients with advanced cancers Open
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
LCCC1613Feasibility Study of a Home-based Exercise Intervention Program for Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Androgen-Deprivation Therapy (ADT)Open
LCCC1619Enhancing Survivorship Care Planning for Patients with Localized Prostate Cancer Using A Couple-focused Web-based Tailored Symptom Self-management ProgramOpen
LCCC1623Interviewing cancer patients and caregivers about using symptom questionnaires to improve quality of cancer careOpen
LCCC1635Pilot study evaluating the microbiome in bladder and prostate cancer patientsOpen
LCCC1636Using PROMIS as part of routine clinical care for racially diverse prostate and bladder cancer patientsOpen
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
RTOG0815A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer Open (affiliates only)